Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT00189969
Other study ID # POX-ELS-001
Secondary ID
Status Completed
Phase Phase 1
First received September 13, 2005
Last updated April 20, 2006
Start date September 2003
Est. completion date February 2006

Study information

Verified date April 2006
Source Bavarian Nordic
Contact n/a
Is FDA regulated No
Health authority Germany: Paul-Ehrlich-Institut
Study type Interventional

Clinical Trial Summary

The purpose of this study is to assess the take rate (formation of a typical postvaccinal lesion)and the safety and immunogenicity of the smallpox vaccine Elstree-BN.


Recruitment information / eligibility

Status Completed
Enrollment 50
Est. completion date February 2006
Est. primary completion date
Accepts healthy volunteers Accepts Healthy Volunteers
Gender Both
Age group 18 Years to 32 Years
Eligibility Inclusion Criteria:

- Signed informed consent

- Free of obvious health problems

- Negative HIV test

- Negative hepatitis B surface antigen and negative antibody to hepatitis C virus

- Hematocrit = 38%; white blood cells between 4.0 and 10.0 / nl with differential blood count without clinical finding; and platelets between 150 and 400 / nl

- ALT < 1.5 times institutional upper limit of normal

- Negative urine glucose by dipstick or urinalysis

- Adequate renal function defined as a serum creatinine < 1.5 mg/dL; urine protein < 100 mg/dL or < 2+ proteinuria; and a calculated creatinine clearance > 55 mL/min.

- For women, negative pregnancy test at screening and within 24 hours prior to vaccination.

- If the volunteer is female and of childbearing potential, she agrees to use acceptable contraception.

Exclusion Criteria:

- Pregnancy or breast-feeding

- Known or suspected history of smallpox vaccination

- Typical vaccinia scar

- Vaccinia specific antibodies at screening

- History of immunodeficiency

- Known or suspected impairment of immunologic function

- Use of immunosuppressive medication or radiation therapy

- Any history of atopic disease

- Eczema of any degree or history of eczema

- Chronic exfoliative skin disorders/conditions or any acute skin disorders of large magnitude

- Any malignancy including leukemia or lymphoma

- Presence of any infectious disease or a history or evidence of autoimmune disease

- History or clinical manifestation of clinically significant mental illness or haematological, renal, hepatic, pulmonary, central nervous, cardiovascular or gastrointestinal disorders

- History of drug or chemical abuse

- Administration of inactivated vaccine 14 days prior to vaccination

- Any immune modifying therapy within 4 weeks prior to vaccination

- Administration of live attenuated vaccines within 60 days prior to vaccination

- Receipt of blood products or immunoglobulin in the past 6 months

- Subjects with acute febrile illness within one week prior to vaccination or subjects who may be in the incubation period of an infectious disease

- Household contacts/sexual contacts with, or occupational exposure to any of the following:

1. Pregnant women

2. Children <12 months of age

3. People with current or history of atopic dermatitis

4. People with chronic exfoliative skin disorders/conditions or any acute skin disorders

5. People with immunodeficiency disease, malignancies or use of immunosuppressive medications

- History of anaphylaxis or severe allergic reaction

- Hypersensitivity to egg or chick protein

- Known allergies to any component of the vaccine or its diluent

- Known allergies to any known component of VIG

- Known allergies to cidofovir or probenecid

- Abnormalities suggestive of any underlying disease, detected at routine tests prior to study inclusion

- Use of any investigational or non-registered drug or vaccine starting 30 days preceding the study vaccine and ending at conclusion visit

- History of myocardial infarction, angina, congestive heart failure, cardiomyopathy, stroke or transient ischemic attack, or other heart condition under the care of a doctor.

- Three or more of the following risk factors: An immediate family member who has had onset of ischemic heart disease before age 50 years, elevated blood pressure, elevated blood cholesterol, diabetes or nicotine abuse.

Study Design

Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention


Related Conditions & MeSH terms


Intervention

Biological:
Elstree-BN


Locations

Country Name City State
Germany Focus Clinical Drug Development GmbH Neuss Nordrhein

Sponsors (1)

Lead Sponsor Collaborator
Bavarian Nordic

Country where clinical trial is conducted

Germany, 

Outcome

Type Measure Description Time frame Safety issue
Primary Occurrence of a typical pock (“take”) which is associated historically with protection against variola within one week after vaccination.
Secondary Occurrence, relationship and intensity of any serious adverse event at any time during the study / any non-serious adverse event within 4 weeks after vaccination.
Secondary ELISA / Neutralisation assay specific seroconversion rates and geometric mean titres 2,4,12,52 and 104 weeks after vaccination.
Secondary Interferone-gamma producing T cells 2,4,12,52 and 104 weeks after vaccination.
See also
  Status Clinical Trial Phase
Completed NCT05976100 - Study of the Safety, Tolerability, Pharmacokinetics of NIOCH-14 in Volunteers Aged 18-50 Years Phase 1
Completed NCT01540929 - Post-licensure Department of Defense (DOD) Screening Accuracy Study in Military Personnel
Completed NCT00258947 - Evaluation of Take and Safety of a Smallpox Vaccine in Healthy Young Adults Phase 2
Terminated NCT00053508 - Dose Safety, Tolerability, and Immunogenicity of a New Smallpox Vaccine in Adults Without Previous Smallpox Vaccination Phase 2
Completed NCT01317238 - Safety and Efficacy of CJ Smallpox Vaccine in Previously Vaccinated Healthy Volunteers Phase 3
Completed NCT01056770 - Safety and Efficacy of CJ Smallpox Vaccine in Healthy Volunteers Phase 3
Withdrawn NCT00389103 - Safety Study of MVA Smallpox Vaccine in Subjects With a History of Atopic Dermatitis (AD) Phase 1
Completed NCT00998543 - A Long-Term Study of Healthy Adults Vaccinated With One Dose of Smallpox Vaccine (LISTER Strain) Phase 2
Terminated NCT00282581 - Safety Study of MVA Smallpox Vaccine in HIV-positive Subjects Who Are Vaccinia Naive Phase 1
Completed NCT00133575 - ACAM 3000 MVA at Harvard Medical School Phase 1/Phase 2
Active, not recruiting NCT00103584 - Safety and Immunogenicity Study of LC16m8, a Modified Smallpox Vaccine, in Healthy, Previously Unvaccinated Volunteers Phase 1/Phase 2
Completed NCT00050505 - Expanded Dryvax Dilution Study in Previously Vaccinated Adults Phase 2
Completed NCT05846243 - Study on Immunogenicity, Reactogenicity and Safety of the VACΔ6 Vaccine in Volunteers Aged 18-60 Years Phase 2/Phase 3
Completed NCT05935917 - Study Evaluating the Bioequivalence of Brincidofovir Form H and Form II Tablets in Healthy Adults Phase 1
Completed NCT00082446 - Combination Study With MVA BN and Dryvax Phase 1
Completed NCT00038987 - Vaccinia Virus Vaccine (APSV) in Vaccinia- Naive Subjects: PILOT Phase 1/Phase 2
Completed NCT05762523 - Safety and Tolerability Study of the VAC∆6 Vaccine in Volunteers Aged 18-40 Years Phase 1
Completed NCT04971109 - Safety, Tolerability and Pharmacokinetics of TPOXX When Administered Orally for 28 Day Phase 3
Completed NCT00646152 - Poly-ICLC to Prevent Respiratory Viral Infections A Safety Study Phase 1
Completed NCT01668537 - A Phase II Trial to Compare a Liquid-frozen and a Freeze-dried Formulation of IMVAMUNE (MVA-BN®) Smallpox Vaccine in Vaccinia-naïve Healthy Subjects Phase 2